Floatz logo

1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER

Previously Treated Myelodysplastic Syndromes

Children's Oncology Groupprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Previously Treated Myelodysplastic Syndromes cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 3BBB
Temsirolimus
National Cancer Institute (NCI)
Phase 2B
PROTEINASE 3 PR1 PEPTIDE
National Cancer Institute (NCI)
Phase 1/2CCC
Daunorubicin
National Cancer Institute (NCI)
Phase 1/2CCC
Montanide Isa 51
National Cancer Institute (NCI)
Phase 1/2CCC

View all 15 →

Same molecule, other indications

1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER is also rated in:

psoriasisDormant
BBB
Indicative ·
76 / 100
View asset →
Pancreatitis, Chronic; Diabetes; TransplantDormant
BB
Indicative ·
68 / 100
View asset →
skin carcinomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →